272 related articles for article (PubMed ID: 27194101)
1. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.
Gerin I; Ury B; Breloy I; Bouchet-Seraphin C; Bolsée J; Halbout M; Graff J; Vertommen D; Muccioli GG; Seta N; Cuisset JM; Dabaj I; Quijano-Roy S; Grahn A; Van Schaftingen E; Bommer GT
Nat Commun; 2016 May; 7():11534. PubMed ID: 27194101
[TBL] [Abstract][Full Text] [Related]
2. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy.
van Tol W; van Scherpenzeel M; Alsady M; Riemersma M; Hermans E; Kragt E; Tasca G; Kamsteeg EJ; Pennings M; van Beusekom E; Vermeulen JR; van Bokhoven H; Voermans NC; Willemsen MA; Ashikov A; Lefeber DJ
Clin Chem; 2019 Oct; 65(10):1295-1306. PubMed ID: 31375477
[TBL] [Abstract][Full Text] [Related]
3. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
Elife; 2021 Jan; 10():. PubMed ID: 33513091
[TBL] [Abstract][Full Text] [Related]
4. PCYT2 synthesizes CDP-glycerol in mammals and reduced PCYT2 enhances the expression of functionally glycosylated α-dystroglycan.
Imae R; Manya H; Tsumoto H; Miura Y; Endo T
J Biochem; 2021 Oct; 170(2):183-194. PubMed ID: 34255834
[TBL] [Abstract][Full Text] [Related]
5. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.
Cataldi MP; Blaeser A; Lu P; Leroy V; Lu QL
Mol Ther Methods Clin Dev; 2020 Jun; 17():271-280. PubMed ID: 31988979
[TBL] [Abstract][Full Text] [Related]
6. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
Kanagawa M; Toda T
J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
[TBL] [Abstract][Full Text] [Related]
7. CDP-glycerol inhibits the synthesis of the functional
Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
[TBL] [Abstract][Full Text] [Related]
8. Human ISPD Is a Cytidyltransferase Required for Dystroglycan O-Mannosylation.
Riemersma M; Froese DS; van Tol W; Engelke UF; Kopec J; van Scherpenzeel M; Ashikov A; Krojer T; von Delft F; Tessari M; Buczkowska A; Swiezewska E; Jae LT; Brummelkamp TR; Manya H; Endo T; van Bokhoven H; Yue WW; Lefeber DJ
Chem Biol; 2015 Dec; 22(12):1643-52. PubMed ID: 26687144
[TBL] [Abstract][Full Text] [Related]
9. Cell endogenous activities of fukutin and FKRP coexist with the ribitol xylosyltransferase, TMEM5.
Nishihara R; Kobayashi K; Imae R; Tsumoto H; Manya H; Mizuno M; Kanagawa M; Endo T; Toda T
Biochem Biophys Res Commun; 2018 Mar; 497(4):1025-1030. PubMed ID: 29477842
[TBL] [Abstract][Full Text] [Related]
10. Oral ribose supplementation in dystroglycanopathy: A single case study.
Thewissen RMJ; Post MA; Maas DM; Veizaj R; Wagenaar I; Alsady M; Kools J; Bouman K; Zweers H; Meregalli PG; van der Kooi AJ; van Doorn PA; Groothuis JT; Lefeber DJ; Voermans NC
JIMD Rep; 2024 May; 65(3):171-181. PubMed ID: 38736632
[TBL] [Abstract][Full Text] [Related]
11. The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition.
Praissman JL; Willer T; Sheikh MO; Toi A; Chitayat D; Lin YY; Lee H; Stalnaker SH; Wang S; Prabhakar PK; Nelson SF; Stemple DL; Moore SA; Moremen KW; Campbell KP; Wells L
Elife; 2016 Apr; 5():. PubMed ID: 27130732
[TBL] [Abstract][Full Text] [Related]
12. Expression in retinal neurons of fukutin and FKRP, the protein products of two dystroglycanopathy-causative genes.
Haro C; Uribe ML; Quereda C; Cruces J; Martín-Nieto J
Mol Vis; 2018; 24():43-58. PubMed ID: 29416295
[TBL] [Abstract][Full Text] [Related]
13. CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model.
Tokuoka H; Imae R; Nakashima H; Manya H; Masuda C; Hoshino S; Kobayashi K; Lefeber DJ; Matsumoto R; Okada T; Endo T; Kanagawa M; Toda T
Nat Commun; 2022 Apr; 13(1):1847. PubMed ID: 35422047
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory machinery for the functional dystroglycan glycosylation.
Kondo Y; Okajima T
J Biochem; 2023 Apr; 173(5):333-335. PubMed ID: 36760122
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular Dystrophy.
Kanagawa M; Kobayashi K; Tajiri M; Manya H; Kuga A; Yamaguchi Y; Akasaka-Manya K; Furukawa JI; Mizuno M; Kawakami H; Shinohara Y; Wada Y; Endo T; Toda T
Cell Rep; 2016 Mar; 14(9):2209-2223. PubMed ID: 26923585
[TBL] [Abstract][Full Text] [Related]
16. The promiscuous binding pocket of SLC35A1 ensures redundant transport of CDP-ribitol to the Golgi.
Ury B; Potelle S; Caligiore F; Whorton MR; Bommer GT
J Biol Chem; 2021; 296():100789. PubMed ID: 34015330
[TBL] [Abstract][Full Text] [Related]
17. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
Cataldi MP; Lu P; Blaeser A; Lu QL
Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
[TBL] [Abstract][Full Text] [Related]
18. Ribitol enhances matriglycan of α-dystroglycan in breast cancer cells without affecting cell growth.
Lu PJ; Tucker JD; Branch EK; Guo F; Blaeser AR; Lu QL
Sci Rep; 2020 Mar; 10(1):4935. PubMed ID: 32188898
[TBL] [Abstract][Full Text] [Related]
19. Compound Heterozygous
Gaertner A; Burr L; Klauke B; Brodehl A; Laser KT; Klingel K; Tiesmeier J; Schulz U; Knyphausen EZ; Gummert J; Milting H
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743126
[TBL] [Abstract][Full Text] [Related]
20. Endogenous reductase activities for the generation of ribitol-phosphate, a CDP-ribitol precursor, in mammals.
Hoshino S; Manya H; Imae R; Kobayashi K; Kanagawa M; Endo T
J Biochem; 2024 Mar; 175(4):418-425. PubMed ID: 38140954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
